Audion Therapeutics Publishes Trial Details on Drug Treatment for Sensorineural Hearing Loss
The Phase I part of the study confirmed the safety and tolerability of a dose of 250 microgram of Gamma Secretase Inhibitor LY3056480.
The Phase I part of the study confirmed the safety and tolerability of a dose of 250 microgram of Gamma Secretase Inhibitor LY3056480.